In its first financing since it was founded in February 2005, Aegerion Pharmaceuticals Inc. raised $22.5 million in an oversubscribed Series A round to fund Phase II development of its lead dyslipidemia drug, AEGR 733. (BioWorld Today)

In its first financing since it was founded in February 2005, Aegerion Pharmaceuticals Inc. raised $22.5 million in an oversubscribed Series A round to fund Phase II development of its lead dyslipidemia drug, AEGR 733. (BioWorld Today)